US House of Representatives moves to repeal PPACA health care law

10 January 2011

The US House of Representatives, which is now led by Republicans following last November’s mid-term elections, is planning to consider a bill (HR 2) - dubbed “Repealing the Job-Killing Health Care Law” - to repeal the major health care legislation enacted last March - that is, the Patient Protection and Affordable Care Act (PPACA) and the provisions of the Health Care and Education Reconciliation Act of 2010 that are related to health care, proposed by the Obama Administration last year.

On January 6, Congressman David Dreier (Republican, California), House Rules Committee Chairman, opened the first Rules Committee hearing of the 112th Congress as the effort to repeal and replace the job-killing health care law got underway. He also introduced H Res 9, a resolution directing relevant House committees to begin the work of drafting replacement provisions that will help increase access to affordable health care coverage.

Rep Dreier made the following statement: “Repealing and replacing the job-killing health care law will be critical to our economic recovery, which is why it is one of our first major orders of business. House Republicans believe we can work to provide access to affordable health care coverage for working Americans and small businesses, and that we can do it without hurting our economy. We need to wipe the slate clean and move quickly into an open and transparent process to produce real solutions to the health care challenges we face. We welcome the ideas of both Republicans and Democrats as this process moves forward. Repealing and replacing the flawed health care law is a pledge we made to the American people, and we are already getting to work.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical